ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 31, 2016

Study Completion Date

May 31, 2017

Conditions
Breast CancerBreast DiseaseNeoplasmsNeoplasms by Site
Interventions
DRUG

Zo-Nantax

"Experimental:~AC,Docetaxel,Trastuzumab,Zolendronate~Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles~Drug: Docetaxel~Docetaxel 100 mg/m2 every 21 days for 4 cycles.~Drug: Trastuzumab~Trastuzumab 8mg/kg \[loading dose\] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.~Drug: zolendronic acid~Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy"

Trial Locations (1)

20560-120

Hospital do Cancer III - INCA, Rio de Janeiro

All Listed Sponsors
lead

Susanne Crocamo

OTHER_GOV

NCT01472146 - ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer | Biotech Hunter | Biotech Hunter